Frank-it’s hard to tell what DECN is good at.
Sales are flat over the past few years. If the products DECN developed were indeed brilliant, they would have generated sales. I thought the Pet strips and price increase on GenUltimate would have would driven increased sales last quarter?
As for the KB loan, that’s all good. The share dilution the past year is an indictment of not getting products to market to generate cash.
This story needs a positive chapter. Couple of months to finalize the licensing agreement. Hard to imagine what is possibly holding it up. GenSure FDA approved yet? Thought it was going to market internationally in Jan-19?
From my view, lack of execution and lack of financing are crippling the company. Don’t you think sentiment would change if the company would deliver against one of its business objectives?
Like the streamlined quarterly. Don’t waste time and resources on stuff that doesn't drive results.
Sales are flat over the past few years. If the products DECN developed were indeed brilliant, they would have generated sales. I thought the Pet strips and price increase on GenUltimate would have would driven increased sales last quarter?
As for the KB loan, that’s all good. The share dilution the past year is an indictment of not getting products to market to generate cash.
This story needs a positive chapter. Couple of months to finalize the licensing agreement. Hard to imagine what is possibly holding it up. GenSure FDA approved yet? Thought it was going to market internationally in Jan-19?
From my view, lack of execution and lack of financing are crippling the company. Don’t you think sentiment would change if the company would deliver against one of its business objectives?
Like the streamlined quarterly. Don’t waste time and resources on stuff that doesn't drive results.
1
